{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:46:30Z","timestamp":1790423190061,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003996","name":"Kunming Medical University","doi-asserted-by":"publisher","award":["2015BS028"],"award-info":[{"award-number":["2015BS028"]}],"id":[{"id":"10.13039\/501100003996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.12.002","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T12:21:13Z","timestamp":1543839673000},"page":"412-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":153,"special_numbering":"C","title":["Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models"],"prefix":"10.1016","volume":"27","author":[{"given":"Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianmei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2018.12.002_bib0001","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/intimm\/dxx037","article-title":"Efficiency of antibody therapy in demyelinating diseases","volume":"29","author":"Akaishi","year":"2017","journal-title":"Int. Immunol."},{"key":"10.1016\/j.msard.2018.12.002_bib0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/2051-5960-2-48","article-title":"Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury","volume":"2","author":"Asavapanumas","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.msard.2018.12.002_bib0003","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/ajts.AJTS_111_16","article-title":"Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica","volume":"11","author":"Batra","year":"2017","journal-title":"Asian J. Transfus. Sci."},{"issue":"1","key":"10.1016\/j.msard.2018.12.002_bib0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bpa.12098","article-title":"Experimental models of neuromyelitis optica","volume":"24","author":"Bradl","year":"2014","journal-title":"Brain Pathol."},{"issue":"9","key":"10.1016\/j.msard.2018.12.002_bib0005","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2018.12.002_bib0006","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/1735-1995.200275","article-title":"Efficacy and safety of rituximab in neuromyelitis optica: review of evidence","volume":"22","author":"Etemadifar","year":"2017","journal-title":"J. Res. Med. Sci."},{"issue":"1","key":"10.1016\/j.msard.2018.12.002_bib0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12974-016-0746-9","article-title":"Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G","volume":"13","author":"Felix","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.msard.2018.12.002_bib0008","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4161\/mabs.26008","article-title":"Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics","volume":"5","author":"Golay","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.msard.2018.12.002_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-2094-5-22","article-title":"Neuromyelitis optica pathogenesis and aquaporin 4","volume":"5","author":"Graber","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.12.002_bib0010","first-page":"77","article-title":"The binding property of a monoclonal antibody against the extracellular domains of aquaporin-4 directs aquaporin-4 toward endocytosis","volume":"7","author":"Huang","year":"2016","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.msard.2018.12.002_bib0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2018.12.002_bib0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40478-015-0207-1","article-title":"Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica","volume":"3","author":"Jones","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.msard.2018.12.002_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jneuroim.2015.10.005","article-title":"The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain","volume":"289","author":"Kang","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2018.12.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7180632","article-title":"Mitochondrial uncoupler prodrug of 2,4-dinitrophenol, mp201, prevents neuronal damage and preserves vision in experimental optic neuritis","author":"Khan","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"4","key":"10.1016\/j.msard.2018.12.002_bib0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of Neuromyelitis Optica: Review and Recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.12.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2817252","article-title":"Targeting oxidative stress for treatment of glaucoma and optic neuritis","author":"Kimura","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.msard.2018.12.002_bib0017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2018.12.002_bib0018","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-015-0259-2","article-title":"Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody","volume":"3","author":"Kurosawa","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.msard.2018.12.002_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin","year":"2013","journal-title":"Prog. Retin Eye Res."},{"issue":"6","key":"10.1016\/j.msard.2018.12.002_bib0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12264-015-1552-6","article-title":"Experimental models of neuromyelitis optica: current status, challenges and future directions","volume":"31","author":"Li","year":"2015","journal-title":"Neurosci. Bull."},{"issue":"1","key":"10.1016\/j.msard.2018.12.002_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","article-title":"The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients","volume":"33","author":"Linhares","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2018.12.002_bib0022","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.msard.2018.12.002_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12974-016-0577-8","article-title":"Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid","volume":"13","author":"Marignier","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"7555","key":"10.1016\/j.msard.2018.12.002_bib0024","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature14335","article-title":"Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo","volume":"522","author":"Najm","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.msard.2018.12.002_bib0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10384-016-0454-0","article-title":"Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica","volume":"60","author":"Nobuyoshi","year":"2016","journal-title":"Jpn. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.msard.2018.12.002_bib0026","first-page":"199","article-title":"Anti-MOG\u202f+\u202fneuromyelitis optica spectrum disorders treated with plasmapheresis","volume":"48","author":"Oshiro","year":"2016","journal-title":"No To Hattatsu"},{"issue":"3","key":"10.1016\/j.msard.2018.12.002_bib0027","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1352458512454771","article-title":"Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis","volume":"19","author":"Quan","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.12.002_bib0028","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2015.03.016","article-title":"The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy","volume":"282","author":"Quan","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2018.12.002_bib0029","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/jcmm.13401","article-title":"Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica","volume":"22","author":"Rosito","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"11","key":"10.1016\/j.msard.2018.12.002_bib0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11940-015-0378-x","article-title":"Acute and chronic management of neuromyelitis optica spectrum disorder","volume":"17","author":"Sherman","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"issue":"2","key":"10.1016\/j.msard.2018.12.002_bib0031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000329576","article-title":"Association of Th1\/Th2-related chemokine receptors in peripheral T cells with disease activity in patients with multiple sclerosis and neuromyelitis optica","volume":"66","author":"Shimizu","year":"2011","journal-title":"Eur. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2018.12.002_bib0032","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4049\/jimmunol.163.1.40","article-title":"Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the \"resistant\" Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response","volume":"163","author":"Stefferl","year":"1999","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2018.12.002_bib0033","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.12.002_bib0034","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-94-024-1057-0_16","article-title":"Aquaporin-targeted therapeutics: state-of-the-field","volume":"969","author":"Tradtrantip","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.msard.2018.12.002_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2018.12.002_bib0036","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study","volume":"4","author":"Valentino","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"12","key":"10.1016\/j.msard.2018.12.002_bib0037","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14728222.2017.1398236","article-title":"The aquaporin-4 water channel as a potential drug target in neurological disorders","volume":"21","author":"Verkman","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.msard.2018.12.002_bib0038","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/jir.2012.0040","article-title":"Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis","volume":"33","author":"Wang","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.msard.2018.12.002_bib0039","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.12.002_bib0040","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2018.12.002_bib0041","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458515617248","article-title":"Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica","volume":"22","author":"Yamasaki","year":"2016","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2018.12.002_bib0042","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40478-016-0309-4","article-title":"Clobetasol promotes remyelination in a mouse model of neuromyelitis optica","volume":"4","author":"Yao","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.msard.2018.12.002_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2016.09.011","article-title":"CD14+CD16++ monocytes are increased in patients with NMO and are selectively suppressed by glucocorticoids therapy","volume":"300","author":"Zeng","year":"2016","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:46Z","timestamp":1761900406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818305303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":43,"alternative-id":["S2211034818305303"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.002","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}